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Flow cytometric analysis of platelets 
type 2 diabetes mellitus reveals ‘angry’ platelets
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Abstract 
Background: The function of platelets have extended way beyond the horizon of haemostasis and thrombosis, and 
are recognised as active participants in vascular inflammation, as well as in prothrombotic complications of cardio-
vascular diseases. We describe and compare platelet function in type II diabetes (with and without cardiovascular 
manifestation) and healthy individuals using scanning electron microscopy and flow cytometry.
Methods: Thirty subjects were recruited per group and informed consent was obtained from all participants. 
Diabetic patients were recruited from the diabetic clinic of the Steve Biko Academic Hospital (South Africa). Blood 
samples were drawn from all participants so that platelet specific antigens were analyzed in citrated whole blood. 
The platelet parameters used in the study were platelet identifiers (CD41 and CD42) and markers of platelet activation 
(CD62 and CD63).
Results: Results show that, compared to healthy individuals, both diabetic groups showed a significant difference 
in both platelet identifiers (CD41-PE, CD42b-PE) as well as markers indicating platelet activation (CD62P-PE and 
CD63-PE).
Interpretation: The flow cytometric data shows that the platelet surface receptors and platelet activation are statisti-
cally elevated. This is suggestive of enhanced platelet activation and it appears as if platelets are displaying ‘angry’ 
behaviour. The lysosomal granules may play a significant role in diabetes with cardiovascular complications. These 
results were confirmed by ultrastructural analysis.
© 2016 Soma et al. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
It is plausible to underestimate the impact of platelets in 
clinical medicine, when one considers that these blood 
cells are only 1.5–3 μm in size, survive for approximately 
8–10  days, and are mere fragments of megakaryocyte 
cytoplasm [1–3]. The function of platelets have extended 
way beyond the horizon of haemostasis and thrombosis. 
In fact, they are now recognised as active participants in 
initiating and sustaining vascular inflammation as well 
as in prothrombotic complications of cardiovascular dis-
eases [1]. Platelets have been assigned multiple attributes 
and have been described in inflammatory conditions 
such as atherosclerosis, arthritis and tumour metasta-
sis [1]. Due to the multifunctional role of platelets, they 
are an accessible and important inflammatory marker 
for disease pathophysiology [4, 5]. Platelets are acti-
vated when they are in contact with damaged vascular 
endothelium [5], and once activated, they are able to 
secrete a wide spectrum of inflammatory mediators that 
exert both local and systemic effects [6].
Platelet activation is also the mechanism implicated 
in the pathogenesis of chronic medical conditions such 
as atherosclerosis, coronary vascular disease and cer-
ebrovascular disease [3]. Due to inflammation there is 
an imbalance between procoagulant and anticoagulant 
properties of the endothelium with subsequent local 
stimulation of the coagulation cascade [7]. Another 
feature of inflammation is a multitude of interactions 
between leukocytes, endothelial cells and platelets. 
More importantly, regardless of its aetiology, inflamma-
tion causes endothelial activation [7]. In diabetes mel-
litus, endothelial dysfunction is one of the mechanism 
ascribed to increased atherothrombotic risk [8]. With 
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cigarette smoking, the endothelium becomes activated 
and induces the intrinsic coagulation pathway. This 
results in platelet activation and enhanced platelet aggre-
gation, which in turn causes thrombin stimulation and 
fibrin formation [9]. Abnormal platelet activation, plate-
let count and volume have been implicated as risk factors 
of ischaemic stroke [10].
Once platelets are activated, they initiate reactions 
whereby changes in the level of expression of surface gly-
coproteins (GP) results, which act as receptors for plate-
let agonists and for adhesive proteins, involved in platelet 
aggregation. Platelet activity can be measured using vari-
ous fluorescently labelled markers in flow cytometry. 
As flow cytometry allows the simultaneous detection 
of surface antigens in a sensitive and specific manner, it 
is therefore possible to examine aspects of the platelet 
membrane activity—see Table 1 for examples of available 
platelet markers.
Platelets in inflammatory conditions
There is a strong indication that platelets also have rel-
evant functions in inflammation [11]. In fact, it was 
shown that thrombosis and inflammation share many key 
molecular mechanisms and that they are fundamentally 
linked processes [7]. It is now recognised that vascular 
inflammation is the key underlying mechanism in athero-
genesis and atheroprogression. The evidence of platelets 
being fundamental mediators in the initiation and main-
tenance of a chronic proinflammatory milieu is provided 
by the direct interactions with inflammatory cells and 
secretion of autocrine and paracrine effector molecules 
[12]. Another emerging concept is the significant role of 
platelet-mediated recruitment of leucocytes in the propa-
gation, progression and pathogenesis of atherosclerotic 
disease. Platelets can interact with leucocytes: (a) during 
haemostasis, when there is vascular damage and recruit 
leucocytes to the growing thrombus, (b) when endothe-
lial cells are stimulated thereby adhering and activat-
ing platelets and then bridge blood-borne leucocytes to 
the vessel wall and (c) in the formation of heterotypic 
aggregates prior to contact with endothelial cells when 
adhesion between platelets and leucocytes occur in the 
blood [13].
It is well known that in subjects with type 2 diabetes 
mellitus, function of platelets is impaired. In fact, a sub-
threshold stimuli is needed to activate platelets which are 
constantly in activation despite the lack of a major plaque 
event and have thus been defined as ‘angry platelets’ [14]. 
This is significant as it has been postulated that circulat-
ing platelets in subjects with untreated type 2 diabetes 
mellitus are in a hyperactive state and are implicated as 
etiologic factors in thrombotic complications [15] which 
are accelerated in diabetics [16]. Of note is the finding of 
hyperactive platelets in metabolically controlled diabetics 
without cardiovascular complications [17]. In addition, 
expression of P-selectin is increased on the surface of 
platelets in patients presenting with symptomatic coro-
nary artery disease, making it a marker of ‘angry platelets’ 
[18].
Diabetes with cardiovascular complication may also 
lead to acute conditions like thrombo-embolic ischemic 
stroke. Multiple studies regarding the activity of platelets 
in acute stroke have been performed. Results obtained 
from these studies (acute ischaemic stroke) showed 
increased mean platelet volume, platelet aggregation 
enhancement in post-ischaemic stroke, increased α-and 
dense granule release and statistically significant increase 
in expression of P-selectin (CD62P), CD63, and throm-
bospondin [19]. The study by Marquardt and co-workers 
investigated the time course of platelet activation after 
ischaemic stroke. They found a significant increase in 
CD62P and CD63 expression within 24  h post cerebral 
ischaemia. In addition, it was also shown that CD62P 
expression declines during the first weeks after stroke, 
whereas CD63 expression remains increased for at least 
3 months after stroke [20].
Another confounding factor together with diabetes is 
cigarette smoking. Multiple studies provides evidence 
on the many adverse effects of smoking on the cardio-
vascular system. This includes: (a) it causes endothelial 
Table 1 Platelet parameters measured in this study
In this study CD41-FITC (fluorescein isothiocyanate) and CD41, Cd42b, CD62, CD63-PE (phycoerythrin) was used
Cluster of differentiation Glycoprotein (GP) Function
CD41 GPIIb Anti-CD41a reacts with platelet membrane GPIIb in the intact complex with GPIIIa but not with GPIIb 
or GPIIIa separately. Useful in the identification and enumeration of platelets
CD42 GPIb Anti-CD42b reacts with platelet membrane GPIb
CD62 P-Selectin Anti-CD62 reacts with α-granule membrane protein which is expressed on the surface of activated 
platelet
CD63 GPIV Anti-CD63 reacts with lysosomal granule-membrane glycoprotein that is expressed on surface of 
activated platelet
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dysfunction [21, 22]; (b) increases inflammation [23]; 
(c) it alters the lipid profile and creates an atherogenic 
setting; (d) promotes atherosclerotic progression by 
enhancing oxidative stress, lipid peroxidation and mito-
chondrial damage [23, 24]; (e) it destabilizes atheroscle-
rotic plaque by increasing matrix metalloproteinases 
[25]; (f ) increases platelet activation and activates coagu-
lation cascade with subsequent atherothrombosis [26, 
27]. Flow cytometric findings in the research by Al-Dahr, 
showed a decrease in CD41b with an increase in CD40 
and CD62 [28]. This paper, therefore investigates the 
functional role of platelets in diabetes, with and with-
out cardiovascular involvement using flow cytometry 




Thirty healthy individuals were used as controls. These 
individuals were non-smokers, who did not use any 
chronic medication and did not have a history of throm-
botic disease. Sixty diabetic subjects (type 2) were 
recruited from the Steve Biko Academic Hospital, dia-
betic clinic in South Africa. Inclusion criteria included: 
(a) subjects older than 18  years and willing to provide 
informed consent, (b) subjects with known diagnosis of 
diabetes, (c) for the cardiovascular group, history of pre-
vious myocardial infarction, peripheral arterial disease, 
stroke or coronary arterial bypass grafting. Exclusion 
criteria included: (a) subjects hemodynamically unsta-
ble and (b) subjected with documented life threatening 
disease (malignancy, HIV/AIDS). Two groups of thirty 
each were distinguished, with and without cardiovascular 
complications. Five millileters of blood was drawn into 
a citrate tube, from each participant. Ethical clearance 
was obtained for this study from the University of Pre-
toria Human Ethics Committee. Informed consent was 
obtained from all participants.
Ultrastructural analysis
Scanning electron microscopy was used to prepare plate-
lets from platelet rich plasma (PRP) according to previ-
ously described methods [29]. Platelets from individuals 
with diabetes, cerebrovascular disease and smoking were 
compared to platelets from healthy individuals.
Flow cytometry
For each blood sample taken four tubes was prepared; 
each tube containing 1  ml sheath fluid from Beckmann 
and Coulter and 20 µl of blood. The various tubes were 
stained with 20 µl of CD41-FITC (fluorescein isothiocy-
anate) and 20  µl of one of the following probes: CD41-
PE (phycoerythrin), CD42b-PE, CD62P-PE and CD63-PE 
(from Beckman Coulter). The samples stained with dif-
ferent probes, were incubated at room temperature in the 
dark for 20 min before being analyzed by a flow cytom-
eter (FC 500, Beckman Coulter). The surface expression 
of platelet receptors was determined by flow cytometry 
using the different monoclonal antibodies as indicated in 
Table 1.
Forward scatter and 90º side scatter were displayed on 
logarithmic scales. Two platelet gates were set. The first 
gate was set according to the morphological characteris-
tics of platelets while the second gate was set according to 
CD41-FITC fluorescence, a platelet specific marker. The 
fluorescence of the different antibodies was plotted on 
256-channel log histograms. The results were expressed 
in arbitrary units as mean channel fluorescence intensity 
(MCFI).
Statistical analysis
For each participant the MCFI was calculated as the 
mean fluorescence of a large sample of platelets (10,000 
platelets per individual), the well-known Central Limit 
Theorem assures us that the Normal distribution is a 
close approximation for the distribution of the MCFIs 
for the experimental groups. GraphPad Prism 5 was 
employed to perform one-way ANOVA for all statisti-
cal analysis, with a p value of ≤0.005 considered signifi-
cant. Post-hoc Dunnett’s Multiple Comparison Test was 
performed to compare the two diabetic groups to the 
controls.
Results
Table 2 shows the demographic data of our study popula-
tion. SEM analysis of the platelets from the three groups 
showed that there is a progressive change in platelet 
structure between the groups. Representative micro-
graphs of the ultrastructure of platelets from healthy 
individuals, and individuals with diabetes (with and with-
out cardiovascular manifestations), are shown in Fig.  1. 
Healthy platelets prepared for SEM, typically show slight 
contact activation, where minimal pseudopodia forma-
tion is visible (Fig.  1a). However, during inflammation, 
platelets form numerous pseudopodia, with microparti-
cle formation, as well as spreading and extensive clump-
ing, which is the hallmark of over-, or hyperactivation. 
This hyperactivation is seen in platelets from individuals 
with diabetes with and without CVD (Fig.  1b, c). How-
ever, diabetic patients with CVD are characterised by an 
increased presence of hyperactivation and microparticle 
formation Fig.  1c. Following the ultrastructural analysis 
we performed flow cytometry on the control and two 
diabetic groups. We found that the ultrastructural results 
were fully supported by the flow cytometry results dis-
cussed below.
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CD41-PE and CD42b-PE MCFI were significantly ele-
vated in both diabetic groups when compared to healthy 
individuals (p value <0.001). CD62P-PE and CD63-PE 
MCFI were significantly decreased for both diabetic 
groups. The percentage activated platelets indicated with 
CD62P-PE and CD63-PE were significantly increased 
in both the diabetic groups. It should be noted that the 
platelet activation indicated CD63-PE showed the dia-
betic group with cardiovascular complication to have the 
largest percentage of activated platelets.
Discussion
Diabetes
Increased expression of platelet activation markers CD31, 
CD36, CD49b, CD62P and CD63 was confirmed by Eibl 
and co-workers when type 2 diabetics were compared 
with normal individuals [30]. In fact, increased expres-
sion of CD63 and CD62, enhanced platelet activation, 
and aggregation are viewed as one of the major causes of 
atherosclerosis and thrombosis in diabetes [31]. CD62P 
is found in the α-granules of platelets and are used as 
markers for activated platelets, while their absence sug-
gests a resting state [32]. A feature that appears strongly 
in diabetics is that of platelet hyperaggregation. This is 
prevalent in both type 1 and type 2 diabetics [33]. From 
a pathophysiological view, this is significant as hyper-
aggregated platelets have a tendency to block blood ves-
sels [5], contributing to atherothrombotic complications 
in diabetics. CD63 is a 53  kDa lysosomal membrane 
protein identified on surface of activated platelets after 
release reaction [34, 35].
Prevention of early platelet adhesion to the damaged 
vessel wall by blocking platelet surface receptors GPIbα 
or GPVI protects from stroke without provoking bleed-
ing complications. In addition, downstream signalling 
of GPIbα and GPVI has a key role in platelet calcium 
homeostasis and activation [36]. The CD42b MoAb used 
in this research, specifically binds to the platelet GPIbα. 
GPIbα forms part of the GPIb-IX-V complex which is 
the receptor for von Willebrand’s factor and is known 
as von Willebrand’s factor-dependant adhesion recep-
tor. According to De Meyer and co-workers in 2011, the 
importance of GPIbα far exceeds that of VWF in arterial 
thrombosis and GPIbα is a central receptor in different 
vascular processes of thrombosis and inflammation, all 
of which may contribute to the progression of ischemic 
stroke [37]. Furthermore, engagement of GPIb-IX-V by 
von Willebrand factor (VWF) mediates platelet adhesion 
to damaged vessels and triggers platelet activation and 
thrombus formation in heart attacks and stroke [38].
Flow cytometric analysis found a significant increase 
in platelet activation regarding CD62 (P-selectin) for the 
diabetics group while the CD62 MCFI values decreased 
compared to the controls as shown in Table 3. This unex-
pected finding may be attributed to the fact that P-selec-
tin can be cleaved from the membrane surface after 
activation releasing P-selectin into the plasma known as 
soluble P-selectin (sP-selectin). The exact mechanism of 
this shedding is unknown but several mechanisms have 
been suggested including cleavage by serum proteases or 
non-specific enzymes or by simple shedding [39]. How-
ever, studies have shown an increase in both P-selectin 
on the surface of platelets and sP-selectin indicating 
that diabetes with or without cardiovascular complica-
tions are associated with chronic activation of platelets 
as P-selectin is being shed from activated platelets and as 
new P-selectin is being expressed on recently activated 
platelet [40]. This study finding echoes results found 
by Véricel et  al. [17] whom also discovered hyperactive 
platelets in metabolically controlled diabetics without 
cardiovascular complications. The diabetic subjects with 
cardiovascular disease, recruited in this study were those 
Table 2 Baseline demographic data and clinical character-
istics of the study population
Data expressed as mean ± (SD) or n (%)
MI myocardial infarction, PAD peripheral arterial disease, CABG coronary arterial 
bypass grafting, ACEI angiotensin converting enzyme inhibitor, Ca-antagonist 
calcium antagonist, HBA1c haemoglobin A1c










Age, years 25 ± 9.64 53 ± 13.7 61 ± 9.4
Males, n (%) 6 (20) 11 (37) 20 (67)
Females, n (%) 24 (80) 19 (63) 10 (33)
Hypertension, n (%) 17 (57) 26 (87)
Diabetic treatment
 Insulin, n (%) 5 (17) 3 (10)
 Oral agents only, n (%) 16 (53) 12 (40)
 Oral and insulin, n (%) 9 (30) 15 (50)
 HBA1c %a 9.0 ± 2.6 8.5 ± 1.7
Cardiovascular complications
 Previous MI, n (%) 19 (63)
 PAD, n (%) 2 (7)
 CABG, n (%) 9 (30)
Essential medication
 ACEI, n (%) 10 (33) 20 (67)
 Ca-antagonist, n (%) 8 (27) 3 (10)
 Β-blocker, n (%) 3 (10) 11 (37)
 Nitrates, n (%) 1 (3) 14 (47)
 Statins, n (%) 10 (33) 25 (83)
 Disprin, n (%) 6 (20) 20 (67)
 Warfarin, n (%) 2 (7) 5 (17)
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with ischaemic events many months and years prior to 
recruitment into this study. Our finding is in keeping 
with persistently hyperactivated platelets.
The CD63 MoAb recognizes the activation-specific 
fusion of the lysosomal granule membrane with the 
plasma membrane, therefore it only binds on the sur-
face of activated platelets and is a useful tool to use in 
the identification of activated platelets [41]. In our study 
CD63 percentage activated platelets were significantly 
increased compared to the healthy controls. The dia-
betic group with cardiovascular complication showed the 
greatest percentage of platelet activation (61.24  % acti-
vation) while the diabetic group without cardiovascular 
complications showed a slightly lower activation percent-
age (54.39 % activation), as shown in Fig. 2. It appears as 
if CVD may play a role in platelet hyperactivation with 
lysosomal involvement.
Conclusion
This study adds to the body of evidence that diabetic 
patients have ‘angry platelets’. Platelet membrane mark-
ers and percentage activated platelets were increased in 
Fig. 1 Micrographs showing representative platelets in (a) a typical platelet as seen in a healthy individual where platelets are disc-shaped with a 
few pseudopodia formation due to contact activation; b Type II diabetes without CVD; arrow shows platelet spreading and pseudopodia formation; 
c Platelets from type II diabetes with CVD now showing extensive spreading and microparticle formation (arrow). Scale bar 1 μm
Table 3 Analysis of control and diabetic groups (with or without CVD), results presented as mean ± standard deviation 
(SD) of MCFI and percentage activated platelets
n = 10,000 platelets total analysed for each participant of each group
Statistically significant differences: * p < 0.001, ** p < 0.005
MoAb Controls (n = 30) Diabetes without CVDs (n = 30) Diabetes with CVD (n = 30)
CD41-PE 21.08 ± 8.74 40.18 ± 14.56* 47.81 ± 24.49*
CD42b-PE 14.43 ± 1.84 24.78 ± 11.98* 24.09 ± 7.27*
CD62P-PE X-mean 30.86 ± 11.37 17.96 ± 1.95* 17.79 ± 2.266*
CD62P-PE % activated platelets 71.01 ± 16.20 92.65 ± 3.67* 92.11 ± 4.31*
CD63-PE X-mean 16.40 ± 3.32 13.05 ± 3.68** 13.38 ± 3.12**
CD63-PE % activated platelets 37.84 ± 17.59 54.39 ± 32.92** 61.24 ± 29.73**
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diabetics with and without CVD. These results support 
and confirm the numerous papers suggesting that plate-
lets play an important and possibly key role in the inflam-
matory profile of diabetic and cardiovascular patients 
and their health should play a key role in a patient-orien-
tated precision medicine approach.
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